Abstract #615: Hispanic People Achieve Clinically Significant Weight loss with Liraglutide 3.0 Mg for Weight Management

2015 ◽  
Vol 21 ◽  
pp. 121
Author(s):  
Patrick O’Neil ◽  
W. Timothy Garvey ◽  
J. Michael Gonzalez-Campoy ◽  
Pablo Mora ◽  
Rafael Violante Ortiz ◽  
...  
Keyword(s):  
Weight Loss ◽  
Weight Management ◽  
Significant Weight Loss ◽  
Hispanic People ◽  
Clinically Significant

scholarly journals Combining ecological momentary assessment, wrist-based eating detection, and dietary assessment to characterize dietary lapse: A multi-method study protocol

2021 ◽  
Vol 7 ◽  
pp. 205520762098821
Author(s):  
Stephanie P Goldstein ◽  
Adam Hoover ◽  
E Whitney Evans ◽  
J Graham Thomas
Keyword(s):  
Weight Loss ◽  
Eating Behavior ◽  
Ecological Momentary Assessment ◽  
Structured Interview ◽  
Self Report ◽  
Significant Weight Loss ◽  
Clinically Significant ◽  
Ecological Momentary ◽  
Momentary Assessment ◽  
Lapse Behavior

Objectives Behavioral obesity treatment (BOT) produces clinically significant weight loss and health benefits for many individuals with overweight/obesity. Yet, many individuals in BOT do not achieve clinically significant weight loss and/or experience weight regain. Lapses (i.e., eating that deviates from the BOT prescribed diet) could explain poor outcomes, but the behavior is understudied because it can be difficult to assess. We propose to study lapses using a multi-method approach, which allows us to identify objectively-measured characteristics of lapse behavior (e.g., eating rate, duration), examine the association between lapse and weight change, and estimate nutrition composition of lapse. Method We are recruiting participants (n = 40) with overweight/obesity to enroll in a 24-week BOT. Participants complete biweekly 7-day ecological momentary assessment (EMA) to self-report on eating behavior, including dietary lapses. Participants continuously wear the wrist-worn ActiGraph Link to characterize eating behavior. Participants complete 24-hour dietary recalls via structured interview at 6-week intervals to measure the composition of all food and beverages consumed. Results While data collection for this trial is still ongoing, we present data from three pilot participants who completed EMA and wore the ActiGraph to illustrate the feasibility, benefits, and challenges of this work. Conclusion This protocol will be the first multi-method study of dietary lapses in BOT. Upon completion, this will be one of the largest published studies of passive eating detection and EMA-reported lapse. The integration of EMA and passive sensing to characterize eating provides contextually rich data that will ultimately inform a nuanced understanding of lapse behavior and enable novel interventions. Trial registration: Registered clinical trial NCT03739151; URL: https://clinicaltrials.gov/ct2/show/NCT03739151

307-OR: Mean Blood Beta-Hydroxybutyrate Predicts Clinically Significant Weight Loss following 90 Days Carbohydrate-Restricted Nutrition Therapy

Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 307-OR
Author(s):  
AMY L. MCKENZIE ◽  
SHAMINIE J. ATHINARAYANAN ◽  
REBECCA N. ADAMS ◽  
BRITTANIE M. VOLK ◽  
STEPHEN PHINNEY ◽  
...  
Keyword(s):  
Weight Loss ◽  
Nutrition Therapy ◽  
Significant Weight Loss ◽  
Clinically Significant ◽  
Beta Hydroxybutyrate

scholarly journals Is 5% weight loss a satisfactory criterion to define clinically significant weight loss?

Obesity ◽  
2015 ◽  
Vol 23 (12) ◽  
pp. 2319-2320 ◽  
Author(s):  
Donald A. Williamson ◽  
George A. Bray ◽  
Donna H. Ryan
Keyword(s):  
Weight Loss ◽  
Significant Weight Loss ◽  
Clinically Significant

scholarly journals Liraglutide for Weight Management in the Real World: Significant Weight Loss Even if the Maximal Daily Dose Is Not Achieved

Obesity Facts ◽  
2021 ◽  
pp. 1-7
Author(s):  
Liesbet Trenson ◽  
Sander Trenson ◽  
Falco van Nes ◽  
Carolien Moyson ◽  
Matthias Lannoo ◽  
...  
Keyword(s):  
Weight Loss ◽  
Body Weight ◽  
Weight Management ◽  
Real World ◽  
Subcutaneous Administration ◽  
Maximum Tolerated Dose ◽  
Significant Weight Loss ◽  
Additional Weight ◽  
Obstructive Sleep ◽  
Daily Dose

<b><i>Introduction:</i></b> Obesity is a global health challenge, and pharmacologic options are emerging. Once daily subcutaneous administration of 3 mg liraglutide, a glucagon like peptide-1 analogue, has been shown to induce weight loss in clinical trials, but real-world effectiveness data are scarce. <b><i>Methods:</i></b> It is a single-centre retrospective cohort study of patients who were prescribed liraglutide on top of lifestyle adaptations after multidisciplinary evaluation. In Belgium, liraglutide is only indicated for weight management if the BMI is &#x3e;30 kg/m<sup>2</sup> or ≥27 kg/m<sup>2</sup> with comorbidities such as dysglycaemia, dyslipidaemia, hypertension, or obstructive sleep apnoea. No indication is covered by the compulsory health care insurance. Liraglutide was started at 0.6 mg/day and uptitrated weekly until 3 mg/day or the maximum tolerated dose. Treatment status and body weight were evaluated at the 4-month routine visit. <b><i>Results:</i></b> Between June 2016 and January 2020, liraglutide was prescribed to 115 patients (77% female), with a median age of 47 (IQR 37.7–54.0) years, a median body weight of 98.4 (IQR 90.0–112.2) kg, a BMI of 34.8 (IQR 32.2–37.4) kg/m<sup>2</sup>, and an HbA1c level of 5.6%. Five (4%) patients did not actually initiate treatment, 9 (8%) stopped treatment, and 8 (7%) were lost to follow-up. At the 4-month visit, the median body weight had decreased significantly by 9.2% to 90.8 (IQR 82.0–103.5) kg (<i>p</i> &#x3c; 0.001). Patients using 3.0 mg/day (<i>n</i> = 60) had lost 8.0 (IQR 5.8–10.4) kg. The weight loss was similar (<i>p</i> = 0.9622) in patients that used a lower daily dose because of intolerance: 7.4 (IQR 6.2–9.6) kg for 1.2 mg (<i>n</i> = 3), 7.8 (IQR 4.1–7.8) kg for 1.8 mg (<i>n</i> = 16), and 9.0 (IQR 4.8–10.7) kg for 2.4 mg/day (<i>n</i> = 14). Weight loss was minimal if liraglutide treatment was not started or stopped prematurely (median 3.0 [IQR 0.3–4.8] kg, <i>p</i> &#x3c; 0.001, vs. on treatment). Further analysis showed an additional weight reduction of 1.8 kg in the patients that had started metformin &#x3c;3 months before the start of liraglutide (<i>p</i> &#x3c; 0.001). The main reasons for liraglutide discontinuation were gastrointestinal complaints (<i>n</i> = 5/9) and drug cost (<i>n</i> = 2/9). <b><i>Conclusion:</i></b> In this selected group of patients, the majority complied with liraglutide treatment over the initial 4-month period and achieved a significant weight loss, irrespective of the maximally tolerated maintenance dose. Addition of metformin induced a small but significant additional weight loss.

scholarly journals A Digital Health Weight Loss Program in 250,000 Individuals

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Conor Senecal ◽  
Robert Jay Widmer ◽  
Beth R. Larrabee ◽  
Mariza de Andrade ◽  
Lilach O. Lerman ◽  
...  
Keyword(s):  
Weight Loss ◽  
Mobile Application ◽  
Weight Control ◽  
Large Scale ◽  
Digital Health ◽  
Large Population ◽  
Weight Loss Program ◽  
Significant Weight Loss ◽  
Face To Face ◽  
Clinically Significant

Importance. Obesity is a worsening epidemic worldwide. Effective and accessible weight loss programs to combat obesity on a large scale are warranted, but a need for frequent face-to-face care might impose a limitation. Objective. To evaluate whether individuals following a weight loss program based on a mobile application, wireless scale, and nutritional program but no face-to-face care can achieve clinically significant weight loss in a large cohort. Design. Retrospective observational analysis. Setting. China from October 2016 to December 2017. Participants. Mobile application users with a minimum of 2 weights (baseline and ≥35 days). Intervention. A commercial (Weijian Technologies) weight loss program consisting of a dietary replacement, self-monitoring using a wireless home scale, and frequent guidance via mobile application. Main Outcome. Mean weight change around 42, 60, 90, and 120 days after program initiation with subgroup analysis by gender, age, and frequency of use. Results. 251,718 individuals, with a mean age of 37.3 years (SD: 9.86) (79% female), were included with a mean weight loss of 4.3 kg (CI: ±0.02) and a mean follow-up of 120 days (SD: 76.8 days). Mean weight loss at 42, 60, 90, and 120 d was 4.1 kg (CI: ±0.02), 4.9 kg (CI: ±0.02), 5.6 kg (CI: ±0.03), and 5.4 kg (CI: ±0.04), respectively. At 120 d, 62.7% of participants had lost at least 5% of their initial weight. Both genders and all usage frequency tertiles showed statistically significant weight loss from baseline at each interval (P<0.001), and this loss was greater in men than in women (120 d: 6.5 vs. 5.2 kg; P<0.001). The frequency of recording (categorized as high-, medium-, or low-frequency users) was associated with greater weight loss when comparing high, medium, and low tertile use groups at all time intervals investigated (e.g., 120 d: −8.6, −5.6, and −2.2 kg, respectively; P<0.001). Conclusions. People following a commercially available hybrid weight loss program using a mobile application, wireless scale, and nutritional program without face-to-face interaction on average achieved clinically significant short- and midterm weight loss. These results support the implementation of comparable technologies for weight control in a large population.

Mental illness as a predictor of patient attendance and anthropometric changes: observations from an Australian publicly funded obesity management service

2020 ◽  
pp. 103985622095371
Author(s):  
Louise Brightman ◽  
Alexandra Dunne ◽  
Hsin-Chia Carol Huang
Keyword(s):  
Mental Illness ◽  
Weight Loss ◽  
Depressive Disorders ◽  
Psychotic Disorders ◽  
Management Service ◽  
Obesity Management ◽  
Significant Weight Loss ◽  
Retrospective Audit ◽  
Schizophrenia Spectrum ◽  
Clinically Significant

Objective: Obesity is associated with co-morbid mental illness. The Canberra Obesity Management Service (OMS) supports adults with severe obesity who have the psychosocial capacity to engage. This study will determine whether mental illness is a predictor of OMS attendance and anthropometric changes. Method: A retrospective audit was performed from July 2016 to June 2017. Baseline characteristics, attendance and anthropometrics were stratified according to the presence of mental illness. Outcomes included weight stabilisation and clinically significant weight loss. Descriptive analyses were performed. Results: Mental illness was present in 60/162 patients (37%). Attendance was similar for those with and without mental illness. Patients with mental illness had twice as many co-morbidities ( p = .001). Depressive disorders were most common ( n = 28, 47%). Anxiety, schizophrenia spectrum and other psychotic disorders, and trauma- and stressor-related disorders also featured. Weight stabilisation was achieved by 25 patients (66%) with mental illness and 25 (35%) without. Clinically significant weight loss was observed in 10 patients (26%) with and 26 (40%) without mental illness. Conclusion: The presence of mental illness did not impact OMS attendance or weight stabilisation. The higher rate of co-morbidities in those with mental illness highlights the challenges faced by this vulnerable population.

Sign in / Sign up

Export Citation Format

Share Document